- Home
- ANTX
as of 02-27-2026 3:55pm EST
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | MENLO PARK |
| Market Cap: | 31.2M | IPO Year: | 2022 |
| Target Price: | $2.00 | AVG Volume (30 days): | 69.0K |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.88 | EPS Growth: | 37.23 |
| 52 Week Low/High: | $1.00 - $1.49 | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -1.22 | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
Stock Insider Trading Activity of AN2 Therapeutics Inc. (ANTX)
Chief Development Officer
Avg Cost/Share
$1.01
Shares
5,956
Total Value
$6,027.47
Owned After
75,823
SEC Form 4
See Remarks
Avg Cost/Share
$1.01
Shares
6,931
Total Value
$7,014.17
Owned After
152,499
SEC Form 4
Chief Strategy Officer
Avg Cost/Share
$1.01
Shares
2,858
Total Value
$2,892.30
Owned After
59,086
SEC Form 4
Chief Development Officer
Avg Cost/Share
$1.00
Shares
3,295
Total Value
$3,304.88
Owned After
75,823
SEC Form 4
See Remarks
Avg Cost/Share
$1.00
Shares
17,923
Total Value
$17,948.09
Owned After
152,499
SEC Form 4
Chief Strategy Officer
Avg Cost/Share
$1.00
Shares
3,604
Total Value
$3,614.81
Owned After
59,086
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Day Lucy | ANTX | Chief Financial Officer | Jan 6, 2026 | Sell | $1.01 | 5,512 | $5,578.14 | 75,363 | |
| Chanda Sanjay | ANTX | Chief Development Officer | Jan 6, 2026 | Sell | $1.01 | 5,956 | $6,027.47 | 75,823 | |
| Eizen Joshua M | ANTX | See Remarks | Jan 6, 2026 | Sell | $1.01 | 6,931 | $7,014.17 | 152,499 | |
| Prior Stephen David | ANTX | Chief Strategy Officer | Jan 6, 2026 | Sell | $1.01 | 2,858 | $2,892.30 | 59,086 | |
| Day Lucy | ANTX | Chief Financial Officer | Jan 5, 2026 | Sell | $1.00 | 3,295 | $3,304.88 | 75,363 | |
| Chanda Sanjay | ANTX | Chief Development Officer | Jan 5, 2026 | Sell | $1.00 | 3,295 | $3,304.88 | 75,823 | |
| Eizen Joshua M | ANTX | See Remarks | Jan 5, 2026 | Sell | $1.00 | 17,923 | $17,948.09 | 152,499 | |
| Prior Stephen David | ANTX | Chief Strategy Officer | Jan 5, 2026 | Sell | $1.00 | 3,604 | $3,614.81 | 59,086 |
Compare ANTX vs Leading Stocks
See how ANTX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ANTX AN2 Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.